Key result
S100A8 and S100A9 aggravate Coxsackievirus B3-induced myocarditis, with S100A9 knockout mice showing improved left ventricular function and reduced viral load compared to wild-type mice.
Why the study?
Do S100A8 and S100A9 aggravate Coxsackievirus B3-induced myocarditis?
Do S100A8 and S100A9 aggravate Coxsackievirus B3-induced myocarditis?
S100A8 and S100A9 aggravate CVB3-induced myocarditis, suggesting they may serve as therapeutic targets in inflammatory cardiomyopathies.
Answers are grounded in this paper and cite their sources.
May identify S100A9 as a myocarditis target; hypothesis-generating, requiring human validation before any clinical consideration.
BACKGROUND: The alarmins S100A8 and S100A9 are damage-associated molecular patterns, which play a pivotal role in cardiovascular diseases, inflammation, and viral infections. We aimed to investigate their role in Coxsackievirus B3 (CVB3)-induced myocarditis. METHODS AND Elimination of CVB3 led to a downregulation of these alarmins. CVB3-infected mice developed an impaired left ventricular function and displayed an increased left ventricular S100A8 and S100A9 protein expression versus controls. In contrast, CVB3-infected S100A9 knockout mice, which are also a complete knockout for S100A8 on protein level, showed an improved left ventricular function, which was associated with a reduced cardiac inflammatory and oxidative response, and lower CVB3 copy number compared with wild-type CVB3 mice. Exogenous application of S100A8 to S100A9 knockout CVB3 mice induced a severe myocarditis similar to wild-type CVB3 mice. In CVB3-infected HL-1 cells, S100A8 and S100A9 enhanced oxidative stress and CVB3 copy number compared with unstimulated infected cells. In CVB3-infected RAW macrophages, both alarmins increased MIP-2 (macrophage inflammatory protein-2) chemokine expression, which was reduced in CVB3 S100A8 knockdown versus scrambled siRNA CVB3 cells. CONCLUSIONS: S100A8 and S100A9 aggravate CVB3-induced myocarditis and might serve as therapeutic targets in inflammatory cardiomyopathies.
No takes yet. Share an insight, caveat, or question.
Müller et al. (2017) studied Coxsackievirus B3-induced myocarditis. S100A8 and S100A9 vs. Controls / wild-type was evaluated on Left ventricular function and viral copy number (p=0.038). S100A8 and S100A9 aggravate Coxsackievirus B3-induced myocarditis, with S100A9 knockout mice showing improved left ventricular function and reduced viral load compared to wild-type mice.
Synapse has enriched 10 related papers. Consider them for comparative context: